CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director Michael Goldberg sold 13,800 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $79.15, for a total value of $1,092,270.00. Following the completion of the sale, the director directly owned 48,526 shares of the company’s stock, valued at approximately $3,840,832.90. This trade represents a 22.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Trading Down 5.3%
Shares of NASDAQ:CDNA traded down $4.16 on Monday, reaching $73.72. 1,030,726 shares of the company were exchanged, compared to its average volume of 981,669. CareDx, Inc. has a 1-year low of $15.15 and a 1-year high of $90.87. The firm has a market cap of $3.87 billion, a price-to-earnings ratio of 30.85 and a beta of 2.50. The company has a 50-day moving average of $66.34 and a 200-day moving average of $36.70.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.45. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The business had revenue of $139.36 million during the quarter, compared to the consensus estimate of $121.96 million. During the same quarter last year, the firm posted $0.03 EPS. The business’s revenue was up 39.3% compared to the same quarter last year. As a group, analysts forecast that CareDx, Inc. will post 1.00 earnings per share for the current year.
Analysts Set New Price Targets
CDNA has been the subject of a number of research reports. Piper Sandler started coverage on shares of CareDx in a research report on Wednesday, November 11th. They set an “overweight” rating and a $100.00 price target for the company. BTIG Research upped their price target on CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Weiss Ratings raised CareDx from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Wall Street Zen cut CareDx from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Finally, Canaccord Genuity Group set a $99.00 target price on CareDx in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, CareDx presently has an average rating of “Moderate Buy” and an average price target of $70.33.
View Our Latest Analysis on CareDx
Institutional Investors Weigh In On CareDx
Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC lifted its stake in shares of CareDx by 759.5% during the 2nd quarter. Squarepoint Ops LLC now owns 141,623 shares of the company’s stock worth $4,036,000 after purchasing an additional 125,146 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of CareDx in the second quarter valued at $1,505,000. Corient Private Wealth LP purchased a new stake in shares of CareDx in the second quarter valued at $654,000. Bank of New York Mellon Corp acquired a new position in CareDx in the second quarter valued at $4,874,000. Finally, Man Group plc acquired a new position in CareDx in the second quarter valued at $3,618,000.
CareDx Company Profile
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also
- Five stocks we like better than CareDx
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
